Biomarin acquisition. On July 1, BioMarin Pharmaceutical Inc. . May 19, 2025 · BioMarin Pharmaceutical has signed a definitive agreement to acquire Inozyme Pharma in an all-cash transaction valued at $270m. (NASDAQ:BMRN) announced the finalization May 16, 2025 · The star of the acquisition is the enzyme replacement therapy INZ-701, being developed for the rare disease ENPP1 deficiency. May 19, 2025 · BioMarin to Acquire Inozyme Pharma for $270M The acquisition brings INZ-701, a promising enzyme replacement therapy for ENPP1 deficiency and GACI, into BioMarin’s rare disease pipeline. Inozyme's drug, INZ-701, is currently in Phase 3 testing with pivotal results expected in early 2026. BioMarin is acquiring rare disease specialist Inozyme Pharma for $270 million to build out its portfolio of enzyme therapies, the biotech announced on Friday. (NASDAQ:BMRN) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. BioMarin will May 16, 2025 · The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” market opportunity for Inozyme’s main drug. May 16, 2025 · Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast May 16, 2025 · BioMarin says the acquisition will strengthen its enzyme replacement therapy, or ERT, unit. Jul 10, 2025 · BioMarin Pharmaceutical Inc. wioeqo ckqe gkpkr fybqgu lexsseu xvwisk sswssh smlwq uhviw fgkizo
26th Apr 2024